Hirudin-Like Factors
A multigene family of thrombin inhibitors with femtomolar affinity
Mechanism Disclaimer
Hirudin is not a single molecule but exists as multiple isoforms. Three principal variants — HV1, HV2, and HV3 — have been characterized from Hirudo medicinalis (Dodt et al.; Scacheri et al.), and additional hirudin-like factors have since been described, consistent with a diversified anticoagulant gene repertoire shaped by the evolutionary pressure of host hemostatic adaptation.
Molecular Architecture
Primary Structure
65 amino acids, approximately 7 kDa. The molecule consists of two functional domains: an N-terminal globular domain stabilized by three disulfide bridges (Cys6-Cys14, Cys16-Cys28, Cys22-Cys39), and a C-terminal acidic tail (residues 49-65) bearing a post-translationally sulfated tyrosine at position 63 (Tyr63-SO3).
Bivalent Binding Mechanism
Hirudin simultaneously engages two thrombin sites: the N-terminal domain blocks the catalytic active site, while the C-terminal tail binds anion-binding exosite I (fibrinogen recognition site). This bridge-like bivalent interaction yields a Kd of 2 × 10⁻¹⁴ M (native, sulfated Tyr63) — the tightest non-covalent protein-protein interaction measured in nature.
Binding Affinity Comparison
Modern Genomic Findings
Multigene Family (2020)
Babenko et al. (2020) genome annotation identified new homologs of genes encoding known anticoagulants, several of them located in tandems or clusters on common scaffolds, which suggests recent local gene duplications; the authors proposed that the functional segregation of hirudin and hirudin-like factor genes could be an example of neofunctionalization.
Tandem-Hirudin (2022)
Lukas et al. (2022) identified Tandem-Hirudin from Hirudinaria manillensis — the first tandem (two-domain) member of the hirudin superfamily. Despite structural homology, this variant shows no thrombin-inhibitory activity, suggesting functional divergence within the family.
Novel Recombinant (2025)
Engineered recombinant hirudin variants continue to be developed as potential next-generation thrombin inhibitors. Cell-free synthesis of hirudin variant 1 has been demonstrated as an alternative production route (Wüstenhagen et al., 2020).
Cell-Free Synthesis
Wüstenhagen et al. (2020) demonstrated successful cell-free protein synthesis of functional hirudin variant 1, bypassing traditional expression systems. Cell-free synthesized hirudin showed considerably higher anti-thrombin activity than recombinant hirudin produced in bacterial cells; K562 lysate with the endogenous signal peptide worked best.
Pharmaceutical Derivatives
| Drug | Hirudin Basis | FDA | Status | Indication |
|---|---|---|---|---|
| Lepirudin (Refludan) | HV1 (desulfatohirudin) | 1998 | Discontinued 2012 (manufacturer ceased production) | HIT-associated thrombosis |
| Desirudin (Iprivask) | HV2 recombinant | 2003 | Active | DVT prophylaxis after hip replacement |
| Bivalirudin (Angiomax) | Hirudin C-terminal + D-Phe-Pro-Arg | 2000 | Active | PCI anticoagulation |
| Dabigatran (Pradaxa) | Not a hirudin derivative: synthetic nonpeptide designed from the inhibitor NAPAP (shares hirudin's target) | 2010 | Active | Stroke prevention in atrial fibrillation |